Search results
13 maj 2024 · Here in this prespecified analysis, we examined effects of semaglutide on weight and anthropometric outcomes, safety and tolerability by baseline body mass index (BMI).
Semaglutide could offer an easier and more reliable way to lose weight and combat the health impacts people with obesity face. Why should this drug, proven to work, not be available to help people change their lives?
10 lut 2021 · Semaglutide is a glucagon-like peptide-1 (GLP-1) analogue that is approved, at doses up to 1 mg administered subcutaneously once weekly, for the treatment of type 2 diabetes in adults and for...
Semaglutide has been shown to increase energy expenditure and promote fat burning, leading to reductions in body weight and improvements in body composition. It may also have a positive impact on lipid metabolism, contributing to favorable changes in cholesterol and triglyceride levels.
Once-Weekly Semaglutide Reduces HbA1c and Body Weight in Patients with Type 2 Diabetes Regardless of Background Common OAD: a Subgroup Analysis from SUSTAIN 2–4 and 10 - PMC. As a library, NLM provides access to scientific literature.
The review found that semaglutide is safe and effective in treating obesity, and complications reported were primarily gastrointestinal events.
Once-weekly semaglutide was associated with reductions in relative and absolute body weight and had beneficial effects on cardiovascular risk factors, such as BMI, waist circumference, and blood pressure.
